Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corp director Wilson Darryl L. exercised restricted stock units into common shares. He converted 1,980 Restricted Stock Units into 1,980 shares of Common Stock at a stated price of $0.00 per share, reflecting settlement of fully vested RSUs. Following the transaction, he directly holds 5,544 shares of Solventum common stock.
Solventum Corp director Wendell Amy McBride exercised fully vested Restricted Stock Units into common stock. McBride converted 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit. Following the transaction, McBride directly holds 7,019 shares of Solventum common stock. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director John H. Weiland exercised equity awards rather than trading in the open market. On March 27, 2026, he exercised 1,980 Restricted Stock Units, each converting into one share of Solventum common stock at a stated price of $0.00 per share.
Following this RSU settlement, Weiland now directly holds 5,544 shares of Solventum common stock. The filing shows no open-market purchases or sales, only the conversion of fully vested RSUs into common shares as part of his equity compensation.
Solventum Corp director Mily Elizabeth exercised fully vested restricted stock units to receive common shares. On March 27, 2026, she exercised 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit.
Following the conversion, she directly holds 5,606 shares of Solventum common stock. The RSU award is now fully settled with no RSUs remaining outstanding from this grant, and there were no open-market purchases or sales reported in this filing.
Solventum Corp director Carlos Alban exercised restricted stock units to receive common shares. On this date, he converted 1,980 fully vested RSUs into 1,980 shares of Solventum common stock at an exercise price of $0.00 per unit. After the transaction, he holds 5,544 common shares directly.
Solventum Corp director Karen J. May exercised restricted stock units to acquire additional shares of common stock. On this date, 1,980 RSUs converted into 1,980 shares of common stock at a stated price of $0.00 per share. Each RSU represented a right to receive one share upon settlement, and the RSUs were fully vested. Following the transaction, May directly holds 5,544 shares of Solventum common stock, reflecting an exercise-and-hold move with no shares sold in this filing.
Solventum Corporation is asking shareholders to vote at its 2026 virtual annual meeting on May 15 on three items: electing four Class II directors, approving an advisory say‑on‑pay resolution, and ratifying PwC as independent auditor.
The proxy highlights Solventum’s first full year as a standalone MedTech company, with 2025 sales of $8.3B, diluted GAAP EPS of $8.88, diluted adjusted EPS of $6.11, reported sales growth of +0.9% and organic sales growth of +3.3%. MedSurg generated 58% of net sales, with Dental Solutions and Health Information Systems each at 16%.
Management underscores portfolio moves, including divesting the Purification & Filtration business to Thermo Fisher Scientific while retaining drinking water filtration, completing its first acquisition (Acera Surgical), and launching a share repurchase program. The Board emphasizes independent leadership with an independent Chair, majority voting for directors, phased declassification by 2028, and robust committee oversight of risk, strategy, talent, and science.
The compensation program is positioned as pay‑for‑performance, with 92% of CEO and 81% of other named executive officer target compensation at risk, heavily weighted to long‑term equity tied to multi‑year revenue, EPS and relative total shareholder return metrics. The Board reports broad 2025 shareholder outreach representing over 56% of outstanding shares (excluding 3M’s 14.7% stake) and cites adding relative TSR to performance share units in response to investor feedback.
Solventum Corp: Amendment to Schedule 13G/A by The Vanguard Group reporting zero beneficial ownership. The filing amends prior disclosures to reflect an internal realignment at The Vanguard Group, stating that certain subsidiaries now report separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership of Common Stock.
Solventum Corporation reported that Chief Accounting Officer Mary Wilcox has informed the company of her intent to retire and will resign from her role after a search for and appointment of her successor. This planned transition is framed as a retirement rather than an immediate or unexpected departure.
Solventum Corp director Wendell Amy McBride bought 1,475 shares of Common Stock in an open-market purchase. The transaction took place on 2026-03-10 at an average price of $68.03 per share. Following this transaction, her direct holdings increased to 5,039 shares of Solventum common stock.